Quipt Home Medical Receives Final Approval for US$3.65 Per Share Acquisition

Quipt Home Medical Corp. has secured final court approval for its plan of arrangement, clearing the path for affiliates of Kingswood Capital Management and Forager Capital Management to acquire all outstanding common shares at US$3.65 per share in an all-cash transaction. The Supreme Court of British Columbia's final order marks a significant milestone for the home medical equipment and services provider, paving the way for the company's delisting from major exchanges following the deal's anticipated closure by March 16, 2026.

The approval represents the culmination of a strategic process that positions the private equity buyers to take full control of the home medical care operator. Following completion of the transaction, Quipt's shares will be removed from trading on both the TSX and NASDAQ, concluding its tenure as a publicly traded entity.

Court Approval and Transaction Timeline

The final order issued by the Supreme Court of British Columbia provides the legal framework necessary to consummate the acquisition. This approval follows shareholder authorization and regulatory clearances, demonstrating broad support for the transaction terms among stakeholders.

Key transaction milestones include:

• Final Court Order: Issued by Supreme Court of British Columbia
• Acquisition Price: US$3.65 per share (all cash)
• Expected Closing Date: On or before March 16, 2026
• Acquirers: Affiliates of Kingswood Capital Management and Forager Capital Management
• Post-Closing Status: Delisting from TSX and NASDAQ

The extended timeline through mid-March 2026 allows for completion of standard closing conditions and regulatory requirements. The court's final approval removes a significant hurdle from the transaction path, signaling to shareholders and creditors that the arrangement has withstood judicial scrutiny regarding fairness and compliance with corporate law requirements.

Market Context and Industry Backdrop

The acquisition of Quipt reflects broader consolidation trends within the home medical equipment (HME) and home healthcare services sectors. These markets have increasingly attracted private capital as demographic trends—particularly an aging population—drive sustained demand for at-home medical support services.

The US$3.65 per share valuation represents a significant investment commitment from the two private equity firms, signaling confidence in Quipt's market position and operational fundamentals. The home medical care industry continues to benefit from several structural tailwinds:

• Aging demographics: Rising number of seniors requiring chronic disease management and mobility assistance
• Healthcare cost pressures: Home-based care typically costs less than institutional alternatives
• Insurance reimbursement stability: Medicare and private insurance coverage for durable medical equipment remains robust
• Consolidation opportunities: Fragmented market allows operators to achieve scale and operational efficiencies

Private equity firms have shown sustained appetite for healthcare services assets, particularly those with recurring revenue models and essential service characteristics. The home medical equipment sector offers both defensive characteristics—essential services with steady demand—and growth optionality through add-on acquisitions and operational improvements.

Investor Implications and Shareholder Considerations

For Quipt shareholders, the final court approval provides certainty regarding transaction completion and the US$3.65 per share cash consideration. The approval removes legal execution risk and substantially increases the probability that shareholders will receive their contractual consideration by the March 2026 deadline.

The acquisition's completion will mark the end of Quipt's public market history on both the TSX and NASDAQ, eliminating ongoing access to market liquidity for existing shareholders at deal closure. Investors holding shares must decide whether to retain positions through closing or exit before delisting, though the court-approved arrangement provides a defined exit mechanism at the agreed purchase price.

For the broader healthcare and medical services investment community, the transaction reinforces several investment themes:

• Private equity interest in essential healthcare services remains robust despite macroeconomic uncertainties
• Home-based care consolidation continues as a viable growth and value-creation strategy
• Valuation multiples in defensive healthcare services sectors attract PE capital seeking stable, predictable returns
• Demographic trends supporting aging-in-place preferences continue driving fundamental demand growth

The deal also demonstrates the continued accessibility of capital for healthcare acquisitions despite broader economic headwinds, suggesting PE firms remain constructive on sector fundamentals and long-term cash flow generation.

Looking Ahead

With final court approval secured, Quipt Home Medical enters the final phase of its transformation from a public company to a privately-held entity under joint control of Kingswood Capital Management and Forager Capital Management. The March 2026 expected closing date provides a clear endpoint for public shareholders to plan their capital allocation strategy.

The approvals and timeline suggest orderly execution ahead, with no major obstacles remaining in the transaction path. As the company approaches delisting, operational continuity remains critical—the home medical equipment and services Quipt provides to patients depend on stable, uninterrupted service delivery. The private ownership structure will likely bring focused operational improvements and potential strategic acquisitions within the fragmented home health market, positioning the company for value creation under its new ownership.